Clinical Trial Update: 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of Avutometinib and Defactinib in malignant brain tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Hemispheric Glioma H3 G34-mutant
• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1, Phase 2 | Status: RECRUITING